Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease
Identifieur interne : 000750 ( Main/Corpus ); précédent : 000749; suivant : 000751Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease
Auteurs : M. Horstink ; E. Tolosa ; U. Bonuccelli ; G. Deuschl ; A. Friedman ; P. Kanovsky ; J. P. Larsen ; A. Lees ; W. Oertel ; W. Poewe ; O. Rascol ; C. SampaioSource :
- European Journal of Neurology [ 1351-5101 ] ; 2006-11.
English descriptors
Abstract
To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.
Url:
DOI: 10.1111/j.1468-1331.2006.01548.x
Links to Exploration step
ISTEX:E570B299EDE8872887F8C9725EFA593752DA0AE8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title><author><name sortKey="Horstink, M" sort="Horstink, M" uniqKey="Horstink M" first="M." last="Horstink">M. Horstink</name><affiliation><mods:affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation><mods:affiliation>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name><affiliation><mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, G" sort="Deuschl, G" uniqKey="Deuschl G" first="G." last="Deuschl">G. Deuschl</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Friedman, A" sort="Friedman, A" uniqKey="Friedman A" first="A." last="Friedman">A. Friedman</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Kanovsky, P" sort="Kanovsky, P" uniqKey="Kanovsky P" first="P." last="Kanovsky">P. Kanovsky</name><affiliation><mods:affiliation>Department of Neurology, Palacky University, Olomouc, Czech Republic</mods:affiliation></affiliation></author><author><name sortKey="Larsen, J P" sort="Larsen, J P" uniqKey="Larsen J" first="J. P." last="Larsen">J. P. Larsen</name><affiliation><mods:affiliation>Department of Neurology, Stavanger University Hospital, Norway</mods:affiliation></affiliation></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name><affiliation><mods:affiliation>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name><affiliation><mods:affiliation>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E570B299EDE8872887F8C9725EFA593752DA0AE8</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1468-1331.2006.01548.x</idno><idno type="url">https://api.istex.fr/document/E570B299EDE8872887F8C9725EFA593752DA0AE8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000750</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title><author><name sortKey="Horstink, M" sort="Horstink, M" uniqKey="Horstink M" first="M." last="Horstink">M. Horstink</name><affiliation><mods:affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation><mods:affiliation>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name><affiliation><mods:affiliation>Department of Neurosciences, University of Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Deuschl, G" sort="Deuschl, G" uniqKey="Deuschl G" first="G." last="Deuschl">G. Deuschl</name><affiliation><mods:affiliation>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</mods:affiliation></affiliation></author><author><name sortKey="Friedman, A" sort="Friedman, A" uniqKey="Friedman A" first="A." last="Friedman">A. Friedman</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Kanovsky, P" sort="Kanovsky, P" uniqKey="Kanovsky P" first="P." last="Kanovsky">P. Kanovsky</name><affiliation><mods:affiliation>Department of Neurology, Palacky University, Olomouc, Czech Republic</mods:affiliation></affiliation></author><author><name sortKey="Larsen, J P" sort="Larsen, J P" uniqKey="Larsen J" first="J. P." last="Larsen">J. P. Larsen</name><affiliation><mods:affiliation>Department of Neurology, Stavanger University Hospital, Norway</mods:affiliation></affiliation></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name><affiliation><mods:affiliation>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name><affiliation><mods:affiliation>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1186">1186</biblScope><biblScope unit="page" to="1202">1202</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">E570B299EDE8872887F8C9725EFA593752DA0AE8</idno><idno type="DOI">10.1111/j.1468-1331.2006.01548.x</idno><idno type="ArticleID">ENE1548</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>management guideline</term><term>neurosurgery</term><term>pharmacotherapy</term><term>review</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>M. Horstink</name><affiliations><json:string>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</json:string></affiliations></json:item><json:item><name>E. Tolosa</name><affiliations><json:string>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</json:string></affiliations></json:item><json:item><name>U. Bonuccelli</name><affiliations><json:string>Department of Neurosciences, University of Pisa, Italy</json:string></affiliations></json:item><json:item><name>G. Deuschl</name><affiliations><json:string>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</json:string></affiliations></json:item><json:item><name>A. Friedman</name><affiliations><json:string>Department of Neurology, Medical University of Warsaw, Poland</json:string></affiliations></json:item><json:item><name>P. Kanovsky</name><affiliations><json:string>Department of Neurology, Palacky University, Olomouc, Czech Republic</json:string></affiliations></json:item><json:item><name>J. P. Larsen</name><affiliations><json:string>Department of Neurology, Stavanger University Hospital, Norway</json:string></affiliations></json:item><json:item><name>A. Lees</name><affiliations><json:string>Reta Lila Weston Institute of Neurological Studies, London, UK</json:string></affiliations></json:item><json:item><name>W. Oertel</name><affiliations><json:string>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</json:string></affiliations></json:item><json:item><name>W. Poewe</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Austria</json:string></affiliations></json:item><json:item><name>O. Rascol</name><affiliations><json:string>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>C. Sampaio</name><affiliations><json:string>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>management guideline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurosurgery</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pharmacotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>review</value></json:item></subject><articleId><json:string>ENE1548</json:string></articleId><language><json:string>eng</json:string></language><abstract>To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.</abstract><qualityIndicators><score>6.74</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1090</abstractCharCount><pdfWordCount>10485</pdfWordCount><pdfCharCount>72380</pdfCharCount><pdfPageCount>17</pdfPageCount><abstractWordCount>145</abstractWordCount></qualityIndicators><title>Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>13</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>17</total><last>1202</last><first>1186</first></pages><issn><json:string>1351-5101</json:string></issn><issue>11</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.1468-1331.2006.01548.x</json:string></doi><id>E570B299EDE8872887F8C9725EFA593752DA0AE8</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E570B299EDE8872887F8C9725EFA593752DA0AE8/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E570B299EDE8872887F8C9725EFA593752DA0AE8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E570B299EDE8872887F8C9725EFA593752DA0AE8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title><author><persName><forename type="first">M.</forename><surname>Horstink</surname></persName><affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</affiliation></author><author><persName><forename type="first">E.</forename><surname>Tolosa</surname></persName><affiliation>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</affiliation></author><author><persName><forename type="first">U.</forename><surname>Bonuccelli</surname></persName><affiliation>Department of Neurosciences, University of Pisa, Italy</affiliation></author><author><persName><forename type="first">G.</forename><surname>Deuschl</surname></persName><affiliation>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</affiliation></author><author><persName><forename type="first">A.</forename><surname>Friedman</surname></persName><affiliation>Department of Neurology, Medical University of Warsaw, Poland</affiliation></author><author><persName><forename type="first">P.</forename><surname>Kanovsky</surname></persName><affiliation>Department of Neurology, Palacky University, Olomouc, Czech Republic</affiliation></author><author><persName><forename type="first">J. P.</forename><surname>Larsen</surname></persName><affiliation>Department of Neurology, Stavanger University Hospital, Norway</affiliation></author><author><persName><forename type="first">A.</forename><surname>Lees</surname></persName><affiliation>Reta Lila Weston Institute of Neurological Studies, London, UK</affiliation></author><author><persName><forename type="first">W.</forename><surname>Oertel</surname></persName><affiliation>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</affiliation></author><author><persName><forename type="first">W.</forename><surname>Poewe</surname></persName><affiliation>Department of Neurology, Innsbruck Medical University, Austria</affiliation></author><author><persName><forename type="first">O.</forename><surname>Rascol</surname></persName><affiliation>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</affiliation></author><author><persName><forename type="first">C.</forename><surname>Sampaio</surname></persName><affiliation>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-11"></date><biblScope unit="volume">13</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1186">1186</biblScope><biblScope unit="page" to="1202">1202</biblScope></imprint></monogr><idno type="istex">E570B299EDE8872887F8C9725EFA593752DA0AE8</idno><idno type="DOI">10.1111/j.1468-1331.2006.01548.x</idno><idno type="ArticleID">ENE1548</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>management guideline</term></item><item><term>neurosurgery</term></item><item><term>Parkinson's disease</term></item><item><term>pharmacotherapy</term></item><item><term>review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E570B299EDE8872887F8C9725EFA593752DA0AE8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="11011"><doi origin="wiley">10.1111/ene.2006.13.issue-11</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue" number="11">11</numbering></numberingGroup><coverDate startDate="2006-11">November 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2006.01548.x</doi><idGroup><id type="unit" value="ENE1548"></id></idGroup><countGroup><count type="pageTotal" number="17"></count></countGroup><titleGroup><title type="tocHeading1">EFNS Task Force Articles</title></titleGroup><eventGroup><event type="firstOnline" date="2006-06-12"></event><event type="publishedOnlineFinalForm" date="2006-10-13"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1186">1186</numbering><numbering type="pageLast" number="1202">1202</numbering></numberingGroup><correspondenceTo>Dr M. W. I. M. Horstink, Department of Neurology, Radboud University Medical Centre, P.O Box 9101, 6500 HB Nijmegen, The Netherlands (tel.: +31 24 361 5202;
fax: +31 24 354 1122; e‐mail: <email>m.horstink@neuro.umcn.nl</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE1548.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 8 March 2006 Accepted 13 March 2006</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count></countGroup><titleGroup><title type="main">Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title><title type="shortAuthors">M. Horstink <i>et al.</i></title><title type="short">Management of late (complicated) Parkinson's disease</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>M.</givenNames><familyName>Horstink</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>E.</givenNames><familyName>Tolosa</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>U.</givenNames><familyName>Bonuccelli</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>G.</givenNames><familyName>Deuschl</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a5"><personName><givenNames> A.</givenNames><familyName>Friedman</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a6"><personName><givenNames>P.</givenNames><familyName>Kanovsky</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a7"><personName><givenNames>J. P.</givenNames><familyName>Larsen</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a8"><personName><givenNames>A.</givenNames><familyName>Lees</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a9"><personName><givenNames>W.</givenNames><familyName>Oertel</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a10"><personName><givenNames>W.</givenNames><familyName>Poewe</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a11"><personName><givenNames>O.</givenNames><familyName>Rascol</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a12"><personName><givenNames> C.</givenNames><familyName>Sampaio</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="NL"><unparsedAffiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="ES"><unparsedAffiliation>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="IT"><unparsedAffiliation>Department of Neurosciences, University of Pisa, Italy</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="DE"><unparsedAffiliation>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="PL"><unparsedAffiliation>Department of Neurology, Medical University of Warsaw, Poland</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="CZ"><unparsedAffiliation>Department of Neurology, Palacky University, Olomouc, Czech Republic</unparsedAffiliation></affiliation><affiliation xml:id="a7" countryCode="NO"><unparsedAffiliation>Department of Neurology, Stavanger University Hospital, Norway</unparsedAffiliation></affiliation><affiliation xml:id="a8" countryCode="GB"><unparsedAffiliation>Reta Lila Weston Institute of Neurological Studies, London, UK</unparsedAffiliation></affiliation><affiliation xml:id="a9" countryCode="DE"><unparsedAffiliation>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="a10" countryCode="AT"><unparsedAffiliation>Department of Neurology, Innsbruck Medical University, Austria</unparsedAffiliation></affiliation><affiliation xml:id="a11" countryCode="FR"><unparsedAffiliation>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="a12" countryCode="PT"><unparsedAffiliation>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">management guideline</keyword><keyword xml:id="k2">neurosurgery</keyword><keyword xml:id="k3">Parkinson's disease</keyword><keyword xml:id="k4">pharmacotherapy</keyword><keyword xml:id="k5">review</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title></titleInfo><titleInfo type="abbreviated"><title>Management of late (complicated) Parkinson's disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Horstink</namePart><affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Tolosa</namePart><affiliation>Neurology Service, Hospital Clínic, Universitat de Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Bonuccelli</namePart><affiliation>Department of Neurosciences, University of Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Deuschl</namePart><affiliation>Department of Neurology, Christian‐Albrechts‐University Kiel, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Friedman</namePart><affiliation>Department of Neurology, Medical University of Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Kanovsky</namePart><affiliation>Department of Neurology, Palacky University, Olomouc, Czech Republic</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. P.</namePart><namePart type="family">Larsen</namePart><affiliation>Department of Neurology, Stavanger University Hospital, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Lees</namePart><affiliation>Reta Lila Weston Institute of Neurological Studies, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Oertel</namePart><affiliation>Philipps‐University of Marburg, Centre of Nervous Diseases, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Poewe</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Rascol</namePart><affiliation>Clinical Investigation Centre, Departments of Clinical Pharmacology and Neurosciences, University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Sampaio</namePart><affiliation>Laboratório de Farmacologia Clinica e Terapeutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2006-11</dateIssued><edition>Received 8 March 2006 Accepted 13 March 2006</edition><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.</abstract><subject lang="en"><genre>Keywords</genre><topic>management guideline</topic><topic>neurosurgery</topic><topic>Parkinson's disease</topic><topic>pharmacotherapy</topic><topic>review</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1186</start><end>1202</end><total>17</total></extent></part></relatedItem><identifier type="istex">E570B299EDE8872887F8C9725EFA593752DA0AE8</identifier><identifier type="DOI">10.1111/j.1468-1331.2006.01548.x</identifier><identifier type="ArticleID">ENE1548</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000750 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000750 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E570B299EDE8872887F8C9725EFA593752DA0AE8
|texte= Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |